Management and strategy consulting for life science companies
6/27/2012 – “High Points and Hurdles: Immunotherapy Moves Forward” by Anita T. Shaffer of OncLive
5/7/2012 – “Insight: Training immune system to fight cancer comes of age” by Bill Berkrot of Reuters
3/2/2012 – “Biotech Stock Mailbag: Cyclacel Fallout, the Skinny on Vivus, Celldex’s Crash” by Adam Feuerstein of TheStreet.com
2/27/2012 – “Dendreon Shares Drop on Slowing Sales of Cancer Vaccine Provenge” by Brett Chase of Minyanville
1/26/2012 – “Amgen, Celgene, Roche Deals Signal M&A Frenzy for Drug Companies” by Brett Chase of Minyanville
1/5/2012 – “Dendreon reports spike in Provenge sales; shares soar” by Bill Berkrot of Reuters
10/11/2011 – “Nobel prize-winning science should incubate deals” by David Holley of The Deal
10/7/2011 – “Zytiga creeps up on Provenge prostate-cancer drug” by Ransdell Pierson of Reuters
8/23/2011 – “What’s a Cancer Drug Worth?” by Brett Chase of Minyanville
October 4, 2012 – MD Becker Partners hosted its 3rd annual “Cancer Immunotherapy: A Long Awaited Reality” conference event in New York. For more information, please Click Here for the Event Website.
September 24, 2012 – “Experts Discuss Challenges and Opportunities in the Development and Manufacturing of Medical Countermeasures; Alliance for Biosecurity and MD Becker Partners Jointly Publish New Industry Roundtable Report” press release
April 12, 2012 – “MD Becker Partners Releases White Paper: 2012 – A Pivotal Year for Alzheimer’s Disease Drug Development” press release
March 11-14, 2012 – MD Becker Partners sponsored ROTH Capital Partners’ 24th Annual Growth Stock Conference in Dana Point, California. Michael Becker also moderated a fireside chat with industry experts titled “Identifying Strategic Value: M&A and Public Market Trends.”
November 10, 2011 – “MD Becker Partners Celebrates Third Successful Year in Business” press release
Legal Disclaimer | © 2013MD Becker Partners LLC • Built on the Genesis Framework